Retraction: Effect of integrin receptor‑targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy (Oncol Lett (2015) 10 (77-84) DOI: 10.3892/ol.2015.3242);Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy

Oncology Letters

Volumn 10, Issue 1, 2015, Pages 77-84

  Chen, Liyu ^a   Liu, Yanbin ^a   Wang, Weiya ^b   Liu, Kai ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Integrin receptor; Liposome; Paclitaxel; Tumor targeting

Indexed keywords

INTEGRIN RECEPTOR; LIPOSOME; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG RELEASE; DRUG SYNTHESIS; ELECTRIC POTENTIAL; ENCAPSULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PARTICLE SIZE; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; TUMOR GROWTH;

EID: 84929886596     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2021.12611     Document Type: Erratum

References (33)

1. Farazi PA and DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 6: 674-687, 2006.
2. Liu X, Wang W and Wang Z: Recent progress in understanding the effects of autophagy in hepatocellular carcinoma. Chin J Hepatobil Surg 20: 69-73, 2014.
3. Pan Y, Ye S, Yuan D, et al: Hydrogen sulfide (H2S)/cystathionine γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells. Mutat Res 763-764: 10-18, 2014.
4. Zhang C, He H, Zhang H, et al: The blockage of Ras/ERK pathway augments the sensitivity of SphK1 inhibitor SKI II in human hepatoma HepG2 cells. Biochem Biophys Res Commun 434: 35-41, 2013.
5. Baek JS, So JW, Shin SC and Cho CW: Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system. Int J Mol Med 30: 953-959, 2012.
6. Sun J, Deng L, Duan Y, et al: Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Exp Ther Med 3: 159-164, 2012.
7. Kimura K, Tanaka S, Iwamoto M, et al: Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncol Lett 6: 881-884, 2013.
8. Tanaka T, Toujima S and Tanaka J: Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Int J Oncol 41: 1837-1844, 2012.
9. Tsukada T, Fushida S, Harada S, et al: Low-dose paclitaxel modulates tumour fibrosis in gastric cancer. Int J Oncol 42: 1167-1174, 2013.
10. Horwitz SB: Taxol (paclitaxel): Mechanisms of action. Ann Oncol 5 (Suppl 6): S3-S6, 1994.
11. Liebmann J, Cook JA and Mitchell JB: Cremophor EL, solvent for paclitaxel and toxicity. Lancet 342: 1428, 1993.
12. Gou Y, Wang L, Lv P and Zhang P: Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer. Oncol Lett 9: 1065-1072, 2015.
13. Despierre E, Lambrechts D, Neven P, et al: The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol 117: 358-365, 2010.
14. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH and Alvarez RD: Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group study. J Clin Oncol 19: 1275-1278, 2001.
15. McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14: 792-795, 1996.
16. Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 17: 2676-2680, 1999.
17. Chua DT, Sham JS and Au GK: A phase II study of docetaxel and cisplatin as first line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral Oncol 41: 589-595, 2005.
18. McCarthy JS, Tannock IF, Degendorfer P, Panzarella T, Furlan M and Siu LL: A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol 38: 686-690, 2002.
19. Yin Y, Wu X, Yang Z, et al: The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension. Pharm Res 30: 2050-2062, 2013.
20. Wender PA, Galliher WC, Goun EA, Jones LR and Pillow TH: The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 60: 452-472, 2008.
21. Lee JH, Engler JA, Collawn JF and Moore BA: Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 268: 2004-2012, 2001.
22. Oba M, Fukushima S, Kanayama N, et al: Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins. Bioconjug Chem 18: 1415-1423, 2007.
23. Li S, Wei J, Yuan L, et al: RGD-modified endostatin peptide 530 derived from endostatin suppresses invasion and migration of HepG2 cells through the αvβ3 pathway. Cancer Biother Radiopharm 26: 529-538, 2011.
24. Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153: 141-148, 2011.
25. Sharma G, Modgil A, Sun C and Singh J: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci 101: 2468-2478, 2012.
26. Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33: 9246-9258, 2012.
27. Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100: 41-52, 2004.
28. Zhang Q, Tang J, Fu L, et al: A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system. Biomaterials 34: 7980-7993, 2013.
29. Qin Y, Chen H, Yuan W, et al: Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 419: 85-95, 2011.
30. Borgne-Sanchez A, Dupont S, Langonné A, et al: Targeted Vpr-derived peptides reach mitochondria to induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell Death Differ 14: 422-435, 2007.
31. Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
32. Fukumura D, Xu L, Chen Y, et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61: 6020-6024, 2001.
33. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 46: 149-168, 2001.